ASP2905

ASP2905 is a 1,3,5-triazine derivative, chemically N-(4-fluorophenyl)-N'-phenyl-N''-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine ^[1]. Its target, KCNH3, also called Kv12.2 or BEC1, is a member of the ether-a-go-go family of voltage-gated potassium channels and is concentrated in the forebrain, a region central to learning, memory, and attention ^[1]. Genetic studies had already linked this channel to cognition, since overexpression impairs cognitive performance in mice while its loss can enhance learning, which made a selective inhibitor an attractive way to boost cognition ^[1].

In cell-based assays ASP2905 potently blocked KCNH3 potassium currents while binding only weakly to a large panel of other transmembrane proteins, indicating good selectivity ^[1]. Given orally, it reversed memory deficits produced by the drugs MK-801 and scopolamine in mice and improved the performance of aged rats in passive-avoidance and water-maze memory tasks, effects seen at very low doses; measurements confirmed that it enters the brain ^[1]. A later study reported antipsychotic-like activity: it suppressed hyperlocomotion induced by methamphetamine and phencyclidine without affecting normal movement, eased phencyclidine-induced behavioral changes, and improved a latent-learning deficit in a neonatal phencyclidine model ^[2].

The pattern of results led its developers to suggest that ASP2905 might address a broad range of schizophrenia symptoms, including positive, negative, and cognitive features, in contrast to conventional antipsychotics that tend to target only some of these ^[2]. ASP2905 remains an entirely preclinical research compound; it has been characterized only in cell and animal studies, and there are no human dosing, efficacy, or safety data. It is not an approved drug or a marketed supplement ^[1][2].

This is preclinical through and through; there is no human data on ASP2905 at all, so its side-effect profile in people is genuinely unknown. Mechanistically, because it works by lifting a brake on neuronal excitability, the sensible class-level caution is overexcitation, meaning effects on seizure threshold at higher exposures are at least a theoretical concern. Mild things like headache or dizziness are plausible but unproven. It is a research chemical, not an approved medicine anywhere, with no established contraindications or interaction data, so treat it as pure frontier territory.

ASP2905 emerged from a drug discovery program at Astellas Pharma aimed at the voltage-gated potassium channel Kv12.2, which is encoded by the Kcnh3 (BEC1) gene and expressed predominantly in the forebrain. Interest in this target grew after genetic work indicated that Kcnh3 influences neuronal excitability and higher cognitive function, prompting a search for selective small-molecule blockers. ASP2905 was characterized as a potent and specific inhibitor of Kv12.2 and was advanced as an experimental probe for disorders featuring cognitive impairment, most notably schizophrenia. Its pharmacology was described in preclinical reports from Astellas researchers, and the compound has remained an investigational tool rather than an approved medicine.

Within the nootropics community ASP2905 is an obscure and largely theoretical entry; it is known chiefly to readers who follow the literature on potassium channel modulation and cognition rather than to hands-on users. Because published data are confined to rodent behavioral models and no meaningful human experience exists, discussion tends to be speculative and cautious. Researchers regard it as an interesting demonstration that selective Kv12.2 blockade can influence learning and stimulant-induced behavior, but it carries none of the established reputation of mainstream cognitive enhancers, and its novel mechanism means safety and efficacy in people are entirely unproven.